Literature DB >> 29286401

Sample Preparation for Endopeptidomic Analysis in Human Cerebrospinal Fluid.

Karl T Hansson1, Tobias Skillbäck2, Elin Pernevik3, Jessica Holmén-Larsson3, Gunnar Brinkmalm3, Kaj Blennow2, Henrik Zetterberg4, Johan Gobom2.   

Abstract

This protocol describes a method developed to identify endogenous peptides in human cerebrospinal fluid (CSF). For this purpose, a previously developed method based on molecular weight cut-off (MWCO) filtration and mass spectrometric analysis was combined with an offline high-pH reverse phase HPLC pre-fractionation step. Secretion into CSF is the main pathway for removal of molecules shed by cells of the central nervous system. Thus, many processes in the central nervous system are reflected in the CSF, rendering it a valuable diagnostic fluid. CSF has a complex composition, containing proteins that span a concentration range of 8 - 9 orders of magnitude. Besides proteins, previous studies have also demonstrated the presence of a large number of endogenous peptides. While less extensively studied than proteins, these may also hold potential interest as biomarkers. Endogenous peptides were separated from the CSF protein content through MWCO filtration. By removing a majority of the protein content from the sample, it is possible to increase the sample volume studied and thereby also the total amount of the endogenous peptides. The complexity of the filtrated peptide mixture was addressed by including a reverse phase (RP) HPLC pre-fractionation step at alkaline pH prior to LC-MS analysis. The fractionation was combined with a simple concatenation scheme where 60 fractions were pooled into 12, analysis time consumption could thereby be reduced while still largely avoiding co-elution. Automated peptide identification was performed by using three different peptide/protein identification software programs and subsequently combining the results. The different programs were complementary rather than comparable with less than 15% of the identifications overlapped between the three.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29286401      PMCID: PMC5755527          DOI: 10.3791/56244

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  23 in total

1.  Orthogonality of separation in two-dimensional liquid chromatography.

Authors:  Martin Gilar; Petra Olivova; Amy E Daly; John C Gebler
Journal:  Anal Chem       Date:  2005-10-01       Impact factor: 6.986

2.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.

Authors:  Bruno Dubois; Howard H Feldman; Claudia Jacova; Harald Hampel; José Luis Molinuevo; Kaj Blennow; Steven T DeKosky; Serge Gauthier; Dennis Selkoe; Randall Bateman; Stefano Cappa; Sebastian Crutch; Sebastiaan Engelborghs; Giovanni B Frisoni; Nick C Fox; Douglas Galasko; Marie-Odile Habert; Gregory A Jicha; Agneta Nordberg; Florence Pasquier; Gil Rabinovici; Philippe Robert; Christopher Rowe; Stephen Salloway; Marie Sarazin; Stéphane Epelbaum; Leonardo C de Souza; Bruno Vellas; Pieter J Visser; Lon Schneider; Yaakov Stern; Philip Scheltens; Jeffrey L Cummings
Journal:  Lancet Neurol       Date:  2014-06       Impact factor: 44.182

Review 3.  Alzheimer's disease.

Authors:  Philip Scheltens; Kaj Blennow; Monique M B Breteler; Bart de Strooper; Giovanni B Frisoni; Stephen Salloway; Wiesje Maria Van der Flier
Journal:  Lancet       Date:  2016-02-24       Impact factor: 79.321

4.  Molecular basis for the effect of urea and guanidinium chloride on the dynamics of unfolded polypeptide chains.

Authors:  Andreas Möglich; Florian Krieger; Thomas Kiefhaber
Journal:  J Mol Biol       Date:  2005-01-07       Impact factor: 5.469

5.  Peptide repertoire of human cerebrospinal fluid: novel proteolytic fragments of neuroendocrine proteins.

Authors:  M Stark; O Danielsson; W J Griffiths; H Jörnvall; J Johansson
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2001-04-25

Review 6.  CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.

Authors:  Bob Olsson; Ronald Lautner; Ulf Andreasson; Annika Öhrfelt; Erik Portelius; Maria Bjerke; Mikko Hölttä; Christoffer Rosén; Caroline Olsson; Gabrielle Strobel; Elizabeth Wu; Kelly Dakin; Max Petzold; Kaj Blennow; Henrik Zetterberg
Journal:  Lancet Neurol       Date:  2016-04-08       Impact factor: 44.182

7.  Peptidome analysis of cerebrospinal fluid by LC-MALDI MS.

Authors:  Mikko Hölttä; Henrik Zetterberg; Ekaterina Mirgorodskaya; Niklas Mattsson; Kaj Blennow; Johan Gobom
Journal:  PLoS One       Date:  2012-08-06       Impact factor: 3.240

8.  In-depth characterization of the cerebrospinal fluid (CSF) proteome displayed through the CSF proteome resource (CSF-PR).

Authors:  Astrid Guldbrandsen; Heidrun Vethe; Yehia Farag; Eystein Oveland; Hilde Garberg; Magnus Berle; Kjell-Morten Myhr; Jill A Opsahl; Harald Barsnes; Frode S Berven
Journal:  Mol Cell Proteomics       Date:  2014-07-18       Impact factor: 5.911

9.  A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans.

Authors:  Mikko Hölttä; Robert A Dean; Eric Siemers; Kwasi G Mawuenyega; Wendy Sigurdson; Patrick C May; David M Holtzman; Erik Portelius; Henrik Zetterberg; Randall J Bateman; Kaj Blennow; Johan Gobom
Journal:  Alzheimers Res Ther       Date:  2016-03-07       Impact factor: 6.982

10.  The worldwide costs of dementia 2015 and comparisons with 2010.

Authors:  Anders Wimo; Maëlenn Guerchet; Gemma-Claire Ali; Yu-Tzu Wu; A Matthew Prina; Bengt Winblad; Linus Jönsson; Zhaorui Liu; Martin Prince
Journal:  Alzheimers Dement       Date:  2016-08-29       Impact factor: 21.566

View more
  1 in total

Review 1.  Small-volume detection: platform developments for clinically-relevant applications.

Authors:  Wei-Hsuan Sung; Yu-Ting Tsao; Ching-Ju Shen; Chia-Ying Tsai; Chao-Min Cheng
Journal:  J Nanobiotechnology       Date:  2021-04-21       Impact factor: 10.435

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.